Overexpression of SKIL was reported in esophageal squamous cell carcinoma (ESCC)16 and breast cancer17, and amplification of SKIL was also found in NSCLC, prostate cancer, and head and neck squamous carcinoma (HNSC)18. Here, SKIL is linked to prostate carcinoma.